Equity - contributed equity

12 Months Ended

Jun. 30, 2020

Note 18. Equity - contributed equity


	Consolidated
	2020 Shares		2019 Shares		2020 $		2019 $

Ordinary shares - fully paid		94,598,369		62,166,673		48,781,214		36,641,519

Movements in Ordinary share capital



Details	Date	Shares		Issue price		$
Balance	1 July 2018		48,409,621				31,575,824
Share placement	24 October 2018		8,900,001	$	0.380		3,382,000
Milestone 1 shares issued in connection with purchase of Glioblast Pty Limited (GDC-0084)	9 November 2018		2,820,824	$	0.440		1,250,000
Issued under Share Purchase Plan	23 November 2018		2,036,227	$	0.380		773,760
Share issue transaction costs			—	$	0.000		(340,065	)


Balance	30 June 2019		62,166,673				36,641,519

Share placement	1 November 2019		10,000,000	$	0.400		4,000,000
Share placement	16 April 2020		18,041,667	$	0.400		7,216,667
Issued under the Share Purchase Plan	11 May 2020		4,390,010	$	0.400		1,756,004
Issued on conversion of options			19	$	4.000		76
Share issue transaction costs			—	$	0.000		(833,052	)


Balance	30 June 2020		94,598,369				48,781,214

Ordinary shares

Ordinary shares entitle the holder to participate in dividends and the proceeds on the winding up of the company in proportion to the number of and amounts paid on the shares held. The fully paid ordinary shares have no par value and the company does not have a limited amount of authorised capital.

On a show of hands every member present at a meeting in person or by proxy shall have one vote and upon a poll each share shall have one vote.

buy-back

There is no current

on-market

buy-back.

Capital risk management

The consolidated entity’s objectives when managing capital are to safeguard its ability to continue as a going concern, so that it can provide returns for shareholders and benefits for other stakeholders and to maintain an optimum capital structure to reduce the cost of capital.

Capital is regarded as total equity, as recognised in the statement of financial position, plus net debt. Net debt is calculated as total borrowings less cash and cash equivalents.

The capital structure of the consolidated entity consists of cash and cash equivalents and equity attributable to equity holders. The overall strategy of the consolidated entity is to continue its drug development programs, which depends on raising sufficient funds, through a variety of sources including issuing of additional share capital, as may be required from time to time.

The capital risk management policy remains unchanged from the prior year.